Effects of Xialiqi Capsules on the expressions of PCNA and caspase-3 in rats withbenign prostatic hyperplasia.
- Author:
Hong-Cai CAI
1
;
Le-Bin SONG
2
;
Guo-Wei ZHANG
1
;
Xing-Rong QING
3
;
Dun-Sheng MO
4
;
Wei LIU
1
;
Xu-Xin ZHAN
5
;
Yu-Feng HUANG
6
;
Xue-Jun SHANG
1
Author Information
1. Department of Andrology, Jinling Hospital Affiliated to Southern Medical University / Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
2. First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210009, China.
3. Family Planning Research Institute/Center of Reproductive Medicine, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
4. Department of Urology, Liuzhou Workers' Hospital / The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
5. Department of Reproductive Medicine, Xi'an No.4 Hospital, Xi'an, Shaanxi 710004, China.
6. Department of Andrology, Jinling Hospital Affiliated to Nanjing University School of Medicine / Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- Keywords:
Xialiqi Capsules;
benign prostatic hyperplasia;
caspase-3;
proliferating cell nuclear antigen;
rat
- MeSH:
Animals;
Capsules;
Caspase 3;
metabolism;
Drugs, Chinese Herbal;
administration & dosage;
pharmacology;
Finasteride;
administration & dosage;
pharmacology;
Male;
Orchiectomy;
Organ Size;
drug effects;
Proliferating Cell Nuclear Antigen;
metabolism;
Prostate;
drug effects;
metabolism;
pathology;
Prostatic Hyperplasia;
drug therapy;
metabolism;
pathology;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
Urological Agents;
administration & dosage;
pharmacology
- From:
National Journal of Andrology
2017;23(8):728-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effects of Xialiqi Capsules(XLQ) on the expressions of the proliferating cell nuclear antigen (PCNA) and caspase-3 in the prostate tissue of the BPH rat model.
METHODS:Fifty male SD ratswereequally randomized into groups A (sham operation control), B (BPH model control), C (high-dose XLQ), D (low-dose XLQ), and E (finasteridecontrol) andthe BPH modelswere established by subcutaneous injection of testosterone propionate at 0.5 mg per kilogram of the body weight per day for 30 days after castration. After modeling, the animals in groups A and B were treated intragastricallywith normal saline, while those in C, D, and E with XLQ at 1.20 and 0.61 g per kilogram of the body weight per day or finasterideat 0.8 mg per kilogram of the body weight per day, respectively, all for 30 days. Then,the bilateral prostates were harvestedfrom the rats for calculation of the prostatic index (prostate wet weight/ body weight) and determination of the expressions of PCNA and caspase-3 in the prostate tissue by immunohistochemistry and immunofluorescence staining, respectively.
RESULTS:The prostate wet weight and prostate index were significantly increased in group B as compared with group A, (［1326±60］ vs［471±17］ g, P<0.01; ［2.89±0.18］ vs ［1.06±0.06］ mg/g, P<0.01), but decreased in groups C (［914±36］ g;［2.02±0.08］ mg/g), D (［1 099±46］g;［2.39±0.11］ mg/g), and E (［817±53］ g;［1.83±0.10］ mg/g)in comparison with B (P<0.01), with statistically significant differences among groups C, D, and E(P<0.01) and most significantly in E.The PCNA level in the prostate tissue wasremarkably higher in group B than in A, but lower in groups C, D and E than in B. The expression of caspase-3 was down-regulatedin group B as compared with A, but up-regulated in groups C, D and E in comparison with B, most significantly in E.
CONCLUSIONS:Xialiqi Capsules can effectively reduce the prostate wet weight and prostatic index of in rats with BPH by inhibiting the level of PCNA and promoting the expression of caspase-3.
